Emergent Biosolutions (CH:ER4)
NYSE:ER4
ER4 Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Durable Cash GenerationSustained positive operating and free cash flow over the trailing twelve months provides durable internal funding for operations, debt service, share repurchases and selective investment. Strong cash conversion increases flexibility through lumpy contract cycles and supports deleveraging efforts.
Improved Leverage And RefinancingMaterial debt reduction and a refinancing that extended maturities and lowered interest costs reduce near‑term refinancing risk and recurring interest burden. The added revolver and delayed draw facility expand liquidity, enabling multi‑year execution of the turnaround and strategic flexibility.
Diversifying Revenue Mix And PartnershipsGrowth in international medical countermeasures, product line extensions for NARCAN and new manufacturing partnerships broaden customers and reduce U.S. concentration. This structural diversification supports steadier, higher‑margin opportunities and lowers single‑market dependence over time.
Bears Say
Revenue Decline And Margin VolatilityThe company has shown substantial swings in revenue and profitability, from strong EBITDA years to net losses. This structural volatility—driven by lumpy orders and commercial pressures—weakens earnings predictability and makes sustained margin improvement and reliable cash flow generation harder to count on.
High Exposure To Government Procurement TimingA large portion of revenue is tied to government purchase orders and stockpile cycles, which are inherently lumpy and timing‑sensitive. That structural dependence increases forecasting risk, working capital swings and revenue concentration, limiting visibility into medium‑term performance.
Reduced R&D Investment May Slow PipelineA marked cut in R&D reduces near‑term cash burn but may impair long‑term innovation and pipeline renewal in a sector where product lifecycle and approvals drive future revenues. Persistently lower R&D heightens reliance on existing products and contract wins to sustain growth.
Emergent Biosolutions News
ER4 FAQ
What was Emergent Biosolutions’s price range in the past 12 months?
Currently, no data Available
What is Emergent Biosolutions’s market cap?
Emergent Biosolutions’s market cap is CHF356.39M.
When is Emergent Biosolutions’s upcoming earnings report date?
Emergent Biosolutions’s upcoming earnings report date is Aug 11, 2026 which is in 45 days.
How were Emergent Biosolutions’s earnings last quarter?
Emergent Biosolutions released its earnings results on Apr 30, 2026. The company reported $0.164 earnings per share for the quarter, beating the consensus estimate of -$0.195 by $0.359.
Is Emergent Biosolutions overvalued?
According to Wall Street analysts Emergent Biosolutions’s price is currently Undervalued.
Does Emergent Biosolutions pay dividends?
Emergent Biosolutions does not currently pay dividends.
What is Emergent Biosolutions’s EPS estimate?
Emergent Biosolutions’s EPS estimate is -0.07.
How many shares outstanding does Emergent Biosolutions have?
Currently, no data Available
What happened to Emergent Biosolutions’s price movement after its last earnings report?
Emergent Biosolutions reported an EPS of $0.164 in its last earnings report, beating expectations of -$0.195. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Emergent Biosolutions?
Currently, no hedge funds are holding shares in CH:ER4
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Emergent Biosolutions Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
18.75%
12-Months-Change
Fundamentals
Return on Equity
-1.59%
Trailing 12-Months
Asset Growth
-7.41%
Trailing 12-Months
Company Description
Emergent Biosolutions
Emergent BioSolutions Inc. is a life sciences company dedicated to providing vital preparedness and response solutions for a wide range of public health threats (PHTs) across the United States. These threats encompass accidental, deliberate, and naturally occurring events, including chemical, biological, radiological, nuclear, and explosives (CBRNE) incidents, emerging infectious diseases, travel-related health risks, and acute emergency care situations. The company's current product portfolio features essential vaccines and treatments such as BioThrax for anthrax and ACAM2000 for smallpox. It also offers Botulism Antitoxin Heptavalent, vaccinia immune globulin intravenous to manage smallpox vaccine complications, and inhalational anthrax therapies like raxibacumab and Anthrasil. Other key offerings include reactive skin decontamination lotion kits, the Trobigard combination drug-device auto-injector, NARCAN nasal spray for emergency opioid overdose reversal, Vivotif, an oral typhoid fever vaccine, and Vaxchora, a single-dose oral cholera vaccine. Emergent is also actively engaged in developing a robust pipeline of future solutions. This includes AP003 (a multidose naloxone nasal spray), AP007 (a sustained-release nalmefene injection for opioid use disorder), AV7909 (an anthrax vaccine), CGRD-001 (a pralidoxime chloride/atropine auto-injector), CHIKV VLP (a chikungunya virus vaccine), COVID-HIG (for SARS-CoV2 treatment), EGRD-001 (a diazepam auto-injector), SIAN (a cyanide poisoning antidote), and UniFlu (a universal influenza vaccine). Furthermore, the company extends its expertise through comprehensive contract development and manufacturing services (CDMO). These services cover drug substance and product manufacturing, packaging, along with technology transfer and advanced process and analytical development. Emergent BioSolutions Inc., founded in 1998, is headquartered in Gaithersburg, Maryland.
ER4 Company Deck
ER4 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call emphasized meaningful operational and financial progress: revenue and adjusted EBITDA exceeded guidance, cash, liquidity and net debt improved materially, refinancing enhanced flexibility, and strategic initiatives (international MCM expansion, product line extensions, manufacturing partnerships) are gaining traction. Notable challenges include comparability to a large 2025 order, constrained U.S. pricing dynamics, an expected $50.4M contingent cash outflow in Q2, and reduced R&D spend. On balance, the positives—strong execution against the turnaround plan, improved balance sheet metrics, and concrete growth catalysts—outweigh the negatives in the near term.View all CH:ER4 earnings summariesER4 Stock 12 Month Forecast
Average Price Target
$9.70
―
Pacira Pharmaceuticals
―
SIGA Technologies
―
ANI Pharmaceuticals
―
Amphastar Pharmaceuticals
―
Options Prices
Currently, No data available
---